Classen Immunotherapies, Inc. v. Elan Pharm., Inc., 20141671 (Fed. Cir. May 13, 2015).
Federal Circuit Reverses Summary Judgment of Noninfringement Under § 271(e)(1) for Consideration of Certain PostFDASubmission Activities, But Expresses Skepticism About Infringement
